Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Precision Health AI

Explore full profile

Precision Health AI is platform tech company that combines modern AI technology with best in class oncology data

New York City, United StatesFounded 2016Biotech & Life Sciences
Valuation $50–100M Last recorded · 2017
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Precision Health AI and the history behind them.

About Precision Health AI

Precision Health AI, also known as PH.AI and Precision Health Intelligence, was an oncology-focused artificial intelligence platform technology company that has since evolved into ConcertAI. The company was founded in New York by Brigham Hyde, Ph.D., a research affiliate at MIT and lecturer at Tufts University with a background in clinical pharmacology and experience in preclinical drug development. In September 2017, the firm emerged from stealth with a significant $20 million Series A investment led by the SymphonyAI Group.

Read full description

The company's primary focus was on applying AI to the field of oncology. It served a diverse client base that included pharmaceutical and life sciences companies, healthcare providers, and payers. The business model revolved around providing data, software applications, and access to its proprietary AI platform, which was named the Eureka Health Oncology AI Platform. This platform was designed to analyze real-world data (RWD) to accelerate drug development, enhance clinical trials, and provide evidence for the broader cancer care ecosystem.

Precision Health AI's core service was its AI platform that processed deep, longitudinal patient data sourced from Electronic Medical Records (EMR), insurance claims, and various diagnostic sources. Through a partnership with the American Society of Clinical Oncology's (ASCO) CancerLinQ program, the company aggregated and de-identified vast amounts of clinical data, including radiology and genomics information. The Eureka Health platform featured over 60 pretrained and learning-enhanced modules specifically designed for oncology. These modules could predict patient outcomes, identify potential adverse drug reactions like chemotherapy-induced neutropenia, and match patients to clinical trials, thereby aiming to provide data-driven, evidence-based decision-making support.

Precision Health AI was a predecessor to ConcertAI, where founder Brigham Hyde also played a co-founding and operational role. ConcertAI continued the mission of leveraging real-world evidence and AI, eventually acquiring the CancerLinQ entity from ASCO in late 2023. Brigham Hyde has since transitioned to become the CEO and co-founder of Atropos Health. Keywords: precision oncology, artificial intelligence, real-world data, cancer research, healthcare data, pharmaceutical services, clinical trial optimization, oncology analytics, EMR data analysis, patient outcome prediction, value-based care, health tech, Brigham Hyde, SymphonyAI, ConcertAI, CancerLinQ, Eureka Health platform, life sciences, HEOR studies, RWD solutions

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
New York City, United States
Open positions
None listed
Dealroom signal
23.0/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, Longevity
Technology
Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Nanotech
Client focus
b2b

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2017 $20M $80M SymphonyAI —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Precision Health AI website traffic

Latest recorded traffic for Precision Health AI is 190 monthly website visits, down 32.1% over the last three months.

Latest monthly visits190 3-month web change-32.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • SymphonyAI
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Precision Health AI on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Precision Health AI’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.